Patient characteristics
| . | n . | % . |
|---|---|---|
| No. with measurable disease | 16 | 94 |
| No. with nonmeasurable disease | 1 | 6 |
| Age | ||
| Median | 58 | |
| Range | 39–73 | |
| Histology | ||
| Papillary serous | 13 | 76 |
| Other | 4 | 24 |
| Initial tumor grade | ||
| 1 | 1 | 6 |
| 2 | 2 | 12 |
| 3 | 14 | 82 |
| Performance status | ||
| 0 | 10 | 59 |
| 1 | 7 | 41 |
| No. of prior chemotherapy regimens | ||
| Median | 2 | |
| Range | (1–5) | |
| Response to first chemotherapy regimen | ||
| CR | 11 | 65 |
| PR | 4 | 24 |
| No response/progression | 1 | 6 |
| Unknown | 1 | 6 |
| Platinum sensitivity | ||
| Sensitive | 8 | 47 |
| Resistant | 9 | 53 |
| Taxane sensitivity | ||
| Sensitive | 8 | 47 |
| Resistant | 9 | 53 |
| Time since last platinum (mo) | ||
| Median | 7 | 41 |
| Range | (1–19) | |
| Time since last paclitaxel (mo) | ||
| Median | 7 | 41 |
| Range | (1–27) |
| . | n . | % . |
|---|---|---|
| No. with measurable disease | 16 | 94 |
| No. with nonmeasurable disease | 1 | 6 |
| Age | ||
| Median | 58 | |
| Range | 39–73 | |
| Histology | ||
| Papillary serous | 13 | 76 |
| Other | 4 | 24 |
| Initial tumor grade | ||
| 1 | 1 | 6 |
| 2 | 2 | 12 |
| 3 | 14 | 82 |
| Performance status | ||
| 0 | 10 | 59 |
| 1 | 7 | 41 |
| No. of prior chemotherapy regimens | ||
| Median | 2 | |
| Range | (1–5) | |
| Response to first chemotherapy regimen | ||
| CR | 11 | 65 |
| PR | 4 | 24 |
| No response/progression | 1 | 6 |
| Unknown | 1 | 6 |
| Platinum sensitivity | ||
| Sensitive | 8 | 47 |
| Resistant | 9 | 53 |
| Taxane sensitivity | ||
| Sensitive | 8 | 47 |
| Resistant | 9 | 53 |
| Time since last platinum (mo) | ||
| Median | 7 | 41 |
| Range | (1–19) | |
| Time since last paclitaxel (mo) | ||
| Median | 7 | 41 |
| Range | (1–27) |